SLN Stock Analysis: Silence Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 540m USD | 12M Return: 172.3% | US82686Q1013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.3M
Qual. Beats: 0
Rev. Trend: -74.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Silence Therapeutics plc (NASDAQ: SLN) is a London-headquartered biotechnology company founded in 1994 (formerly SR Pharma, renamed in 2007) that develops therapeutics based on short interfering RNA (siRNA), a technology that silences the expression of specific disease-causing genes at the post-transcriptional level. The company is focused on hematology, cardiovascular, and rare diseases, with a clinical pipeline led by Divesiran (SLN124) in Phase 2 for polycythemia vera and Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), alongside earlier-stage candidates including SLN548, SLN312, SLN365, and SLN098. As a clinical-stage biopharmaceutical firm with no marketed products, Silences business model centers on advancing its siRNA platform through R&D and strategic partnerships, generating value primarily through pipeline milestones and licensing rather than product sales.
- Divesiran Phase 2 polycythemia vera data readout approaches
- Zerlasiran Phase 2 Lp(a) cardiovascular trial results pending
- Cash runway narrows as small-cap siRNA developer faces dilution
| Net Income: -60.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.09 > 0.02 and ΔFCF/TA -75.04 > 1.0 |
| NWC/Revenue: 13.3k% < 20% (prev 515.3%; Δ 12.8k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -42.3m > Net Income -60.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.7m) vs 12m ago 0.01% < -2% |
| Gross Margin: 51.00% > 18% (prev 82.41%; Δ -31.41% > 0.5%) |
| Asset Turnover: 0.45% > 50% (prev 15.71%; Δ -15.26% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.77 (Total Current Assets 94.3m - Total Current Liabilities 12.7m) / Total Assets 106.4m |
| B: -5.54 (Retained Earnings -589.6m / Total Assets 106.4m) |
| C: -0.45 (EBIT TTM -60.8m / Avg Total Assets 135.8m) |
| D: 0.57 (Book Value of Equity 38.5m / Total Liabilities 67.9m) |
| Altman-Z'' = -15.45 = D |
| DSRI: 3.0 (Receivables 9.29m/20.0m, Revenue 614k/26.0m) |
| GMI: 1.62 (GM 82.41% / 51.00%) |
| AQI: 1.12 (AQ_t 0.10 / AQ_t-1 0.09) |
| SGI: 0.02 (Revenue 614k / 26.0m) |
| TATA: -0.17 (NI -60.0m - CFO -42.3m) / TA 106.4m) |
| Beneish M = -1.47 (Cap -4..+1) = D |
As of October 20, 2026, the stock is trading at USD 19.58 with a total of 71,905,098 shares traded. Over the past week, the price has changed by +102.90%, over one month by +59.84%, over three months by +86.65% and over the past year by +172.32%.
Current recommended Stop Loss: 18.70 (which is 4.5% or 1.3 ATR below the current price).
Silence Therapeutics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy SLN.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 33 | 68.5% |
P/S = 877.2317
P/B = 18.5957
Revenue TTM = 614k USD
EBIT TTM = -60.8m USD
EBITDA TTM = -60.3m USD
Long Term Debt = 9.00k USD (estimated: total debt 112k - short term 103k)
Short Term Debt = 103k USD (from shortTermDebt, last quarter)
Debt = 112k USD (from shortLongTermDebtTotal, last quarter) (leases 112k already included)
Net Debt = -38.5m USD (calculated: Debt 112k - CCE 38.6m)
Enterprise Value = 501.0m USD (539.5m + Debt 112k - CCE 38.6m)
Interest Coverage Ratio = unknown (Ebit TTM -60.8m / Interest Expense TTM 0.0)
EV/FCF = -4.31x (Enterprise Value 501.0m / FCF TTM -116.4m)
FCF Yield = -23.23% (FCF TTM -116.4m / Enterprise Value 501.0m)
FCF Margin = -18.9k% (FCF TTM -116.4m / Revenue TTM 614k)
Net Margin = -9.76k% (Net Income TTM -60.0m / Revenue TTM 614k)
Gross Margin = 51.00% ((Revenue TTM 614k - Cost of Revenue TTM 301k) / Revenue TTM)
Gross Margin QoQ = none% (prev 72.28%)
Tobins Q-Ratio = 4.71 (Enterprise Value 501.0m / Total Assets 106.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 112k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -48.0m (EBIT -60.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 94.3m / Total Current Liabilities 25.3m)
Debt / Equity = 0.00 (Debt 112k / totalStockholderEquity, last quarter 38.5m)
Debt / EBITDA = 0.64 (negative EBITDA) (Net Debt -38.5m / EBITDA -60.3m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -38.5m / FCF TTM -116.4m)
Total Stockholder Equity = 56.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.14% (Net Income -60.0m / Total Assets 106.4m)
RoE = -106.9% (Net Income TTM -60.0m / Total Stockholder Equity 56.1m)
RoCE = -108.4% (out of range, set to none) (EBIT -60.8m / Capital Employed (Equity 56.1m + L.T.Debt 9.00k))
RoIC = -51.20% (negative operating profit) (NOPAT -48.0m / Invested Capital 93.8m)
WACC = 9.09% (E(539.5m)/V(539.6m) * Re(9.09%) + D(112k)/V(539.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.23 | Cagr: 3.25%
[DCF] Fair Price = unknown (Cash Flow -116.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: -74.78 | Revenue CAGR: -74.27% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.09 | Chg30d=+50.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.36 | Chg30d=+49.66% | Revisions=+25% | GrowthEPS=+80.2% | GrowthRev=-22.3%
EPS next Year (2027-12-31): EPS=-0.38 | Chg30d=+50.33% | Revisions=+25% | GrowthEPS=-4.1% | GrowthRev=+130.9%
[Analyst] Revisions Ratio: +50% (up=3, down=0)